Inventiva S.A. (NASDAQ:IVA – Get Free Report) shares fell 2.8% during mid-day trading on Tuesday . The company traded as low as $2.11 and last traded at $2.11. 5,585 shares were traded during mid-day trading, an increase of 7% from the average session volume of 5,223 shares. The stock had previously closed at $2.17.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on IVA. HC Wainwright decreased their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, October 15th. Stifel Nicolaus decreased their price objective on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a report on Friday, November 22nd. Finally, UBS Group assumed coverage on shares of Inventiva in a research note on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 target price on the stock.
Inventiva Stock Performance
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Stories
- Five stocks we like better than Inventiva
- High Dividend REITs: Are They an Ideal Way to Diversify?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- The Role Economic Reports Play in a Successful Investment Strategy
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- Upcoming IPO Stock Lockup Period, Explained
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
